Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7446603 in Diabetic Macular Edema
NCT06850922Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Fab Fragments
- Countries
- 3
01
Overview
Phase 2 trial of RG6351 in diabetic macular edema (DME) (5 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events, Percentage of Participants With Ocular Adverse Events and 1 more. Started Jun 2022; status: completed.
02
Drugs
RG6351
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06850922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850922.